AzTrials
AzTrials

Tuberculosis, PulmonaryTBMaskNCT04938596

Airborne Preventive Measures to Reduce New TB Infections in Household Contacts

A study testing Respiratory bundle in people with Tuberculosis, Pulmonary and Household Contacts, run by Pontificia Universidad Catolica de Chile at 1 site in Chile.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case… Read more about this study

Who is it for?
Any age
What is being tested?
Respiratory bundle
Could I receive a placebo?
No, everyone receives an active treatment
How many people
432 participants
Where
1 siteChile
Study dates
4 Oct 2021to 30 Mar 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • all household contacts of a new case of pulmonary TB (smear, culture or PCR positive) newly diagnosed at each clinic.

Who cannot join

  • household contacts found to have co-prevalent active TB at enrolment
  • household contacts planning to leave the house at the time of enrolment
  • household contacts of index cases having already initiated TB treatment for > 48h
  • household contacts of index cases that are currently hospitalized

Trial locations and contacts

1 site in 1 country.

Chile1 site
  • Pontificia Universidad Católica de Chile

    Santiago

Other trials in Chile

About this study

Official title: Strengthening of Airborne Preventive Measures Inside Households of Pulmonary TB Cases as a Tool to Reduce New Infections in Close Contacts. A Pilot, Controlled, Pre-post Study.

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case, can reduce new TB infections in close contacts. For this purpose, a pilot, controlled, pre-post study will be set up, to evaluate the feasibility of implementing a bundle of respiratory precautions to all household contacts of new pulmonary TB cases, compared to standard of care, in primary health care in a high TB incidence area in Santiago, Chile.

Read the detailed description

Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). In 2018, an estimated 10 million people fell ill with TB worldwide, and more than 1.4 million people died from it, making eradication of this disease in the next decades highly unlikely unless new interventions are discovered. Mycobacterium tuberculosis (Mtb) transmission mainly occurs when patients affected by laryngeal or pulmonary TB cough upon others and the mycobacteria are spread in airborne droplets nuclei smaller than 5 μm that are subsequently inhaled by close contacts. Although chemoprophylaxis once a new TB infection is detected is an effective strategy to reduce the risk of contacts developing active TB, it does not prevent Mtb acquisition; it only reduces the risk of developing active TB once infected. Currently, the large majority of international guidelines recommend strict measures to reduce airborne transmission in hospitalized patients with pulmonary TB, with a minimum of 2 weeks of effective TB therapy to consider a patient no longer infectious and discontinue respiratory isolation in healthcare settings. On the contrary, in the community, no special recommendations regarding protection of household contacts are specified, assuming that most of them are already infected and that the TB index case will stop infecting very quickly under antimicrobial treatment. However, several studies show that median time to sputum Mtb culture conversion under effective treatment takes 5-7 weeks, raising the potential for continued transmission even despite effective treatment. Furthermore, a previous study has shown that in Santiago, Chile, 55% of household contacts of TB cases have no evidence of TB infection at the time of diagnosis of the index case - as categorized by negative latent TB testing - yet under close follow-up, up to 21% of these show new evidence of having acquired the infection based on latent TB test conversion after 12 weeks of follow-up. The investigators hypothesize that reducing respiratory exposure within the household, during the first weeks of TB treatment initiation of the index case, can reduce new TB infections in close contacts. For this purpose, a pilot, controlled, pre-post study will be done to evaluate the feasibility of implementing a bundle of respiratory precautions to all household contacts of new pulmonary TB cases, compared to standard of care, in primary care in a high TB incidence area in Santiago. The respiratory bundle in the intervention arm will be implemented as soon as a new pulmonary TB case is diagnosed, will last 2 weeks and, will include: (a) provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, (b) recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others, (c) promotion of strategies to improve house ventilation; and (d) education about TB transmission. The investigators expect to show that this trial is feasible to proceed with a larger, definitive cluster randomized controlled trial that will evaluate the intervention effectiveness in reducing the incidence of new TB infections in household contacts. The results of this study will help to answer a critical research gap in TB infection control and prevention and, it will provide a key contribution to future policies regarding TB control and elimination worldwide. Furthermore, in the new global context of rising infectious agents of pandemic risk, this work may have an additional potential relevance with respect to the use, acceptability and transmission prevention potential of a respiratory bundle in the household setting regarding other respiratory pathogens such as SARS-Cov-2.

Being tested
Respiratory bundle
Medical subject headings
Tuberculosis, Pulmonary, Tuberculosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Respiratory bundleCombination product

    • Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks
    • Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks
    • Promotion of strategies to improve house ventilation during 2 weeks
    • Provision of a TB leaflet and nurse education about TB transmission.
Study groups in NCT04938596
Study groupRoleWhat they receive
Respiratory Bundle GroupExperimentalThe intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.
Receives: Combination Product: Respiratory bundle
Standard of careNo interventionUnder current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Participation rate

    To document the proportion of TB cases and household contacts who agree to participate as measured by enrollment.

    Measured: 2 weeks

  2. Study compliance

    To document participants compliance with the respiratory bundle as measured by a previously validated adherence questionnaire.

    Measured: 2 weeks

  3. Completion rate

    The number of participants assessable at end of follow-up.

    Measured: 12 weeks

  4. Acceptability of the intervention

    Focus group evaluation (participants and TB nurses perspectives, qualitative outcome).

    Measured: 12 weeks

Secondary outcomes (1)
  1. New tuberculosis infections

    The number of participants converting from a negative to a positive latent TB test at follow-up.

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2021
  2. Study start4 Oct 2021
  3. Primary completion30 Mar 2024
  4. Study completion30 Mar 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, semi-experimental, controlled trial. Two different health care areas of Santiago (and their corresponding TB clinics) will be allocated to control or intervention arm; after a baseline pre-intervention period.
Masking
None (open label)
Enrolment
432 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04938596
Sponsor's protocol ID
1211225
Acronym
TBMask
Status last verified
May 2024
First submitted
12 May 2021
Last updated
13 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Ruiz-Tagle C, Seguel R, Villarroel L, Bernales M, Vargas-Garcia S, Pizarro A, Pena C, Neira V, Garcia P, Allel K, Nathavitharana RR, Balcells ME. Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial. Clin Infect Dis. 2026 Feb 25;82(2):291-298. doi: 10.1093/cid/ciaf526.

    PubMed 41003685

Questions about this trial

What is this clinical trial studying?

A study testing Respiratory bundle in people with Tuberculosis, Pulmonary and Household Contacts, run by Pontificia Universidad Catolica de Chile at 1 site in Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Participation rate (time frame: 2 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04938596, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in